266 related articles for article (PubMed ID: 26612480)
1. Phase II study of everolimus in refractory testicular germ cell tumors.
Mego M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rajec J; Sycova-Mila Z; Chovanec M; Rejlekova K; Zuzák P; Ondrus D; Spanik S; Reckova M; Mardiak J
Urol Oncol; 2016 Mar; 34(3):122.e17-22. PubMed ID: 26612480
[TBL] [Abstract][Full Text] [Related]
2. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer.
Mego M; Svetlovska D; Chovanec M; Rečkova M; Rejlekova K; Obertova J; Palacka P; Sycova-Mila Z; De Giorgi U; Mardiak J
Invest New Drugs; 2019 Aug; 37(4):748-754. PubMed ID: 31152292
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
5. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
[TBL] [Abstract][Full Text] [Related]
6. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
7. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
8. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
Mego M; Svetlovska D; Angelis V D; Kalavska K; Lesko P; Makovník M; Obertova J; Orszaghova Z; Palacka P; Rečková M; Rejlekova K; Z SM; Mardiak J; Chovanec M
Invest New Drugs; 2022 Oct; 40(5):1080-1086. PubMed ID: 35763178
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Klaproth H; Kubin T; Sayer HG; Hentrich M; Welslau M; Mayer F; Kuczyk M; Spott C; Kanz L; Bokemeyer C
Br J Cancer; 2002 Sep; 87(7):729-32. PubMed ID: 12232755
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience.
Faure-Conter C; Orbach D; Cropet C; Baranzelli MC; Martelli H; Thebaud E; Vérité C; Rome A; Fasola S; Corradini N; Rocourt N; Frappaz D; Kalfa N; Patte C
Pediatr Blood Cancer; 2014 Feb; 61(2):253-9. PubMed ID: 23940114
[TBL] [Abstract][Full Text] [Related]
13. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.
Oing C; Hentrich M; Lorch A; Gläser D; Rumpold H; Ochsenreither S; Richter S; Dieing A; Zschäbitz S; Pereira RR; Bokemeyer C; Seidel C
J Cancer Res Clin Oncol; 2020 Feb; 146(2):449-455. PubMed ID: 31838576
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Massarelli E; Lin H; Ginsberg LE; Tran HT; Lee JJ; Canales JR; Williams MD; Blumenschein GR; Lu C; Heymach JV; Kies MS; Papadimitrakopoulou V
Ann Oncol; 2015 Jul; 26(7):1476-80. PubMed ID: 26025965
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
18. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
Oechsle K; Honecker F; Cheng T; Mayer F; Czaykowski P; Winquist E; Wood L; Fenner M; Glaesener S; Hartmann JT; Chi K; Bokemeyer C; Kollmannsberger C
Ann Oncol; 2011 Dec; 22(12):2654-2660. PubMed ID: 21415240
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Kollmannsberger C; Nichols C; Bokemeyer C
Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
